The short version of peptide hormone fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
== History == Deramciclane was discovered by EGIS Pharmaceuticals Ltd in Budapest, Hungary. In 2000, EGIS signed over exclusive rights to Orion Pharma to further develop, register, and market deramciclane. Successful pre-clinical, Phase I, and Phase II trials looked promising to the company and its investors even up until the third quarter of 2002. Phase I studies show little to no side effects of deramciclane. Phase II studies show little to no side effects and statistically significant improvement on the Hamilton Anxiety Rating Scale in response to daily 60 mg doses, but not in response to daily 10 or 30 mg doses. Finally, in February, 2003, deramciclane development for use against general anxiety disorder (GAD) was discontinued during Phase III trials due to clinically insignificant results compared to placebo groups.
Advanced imaging may predict conversion from prodromal stages (mild cognitive impairment) to Alzheimer's disease. FDA-approved radiopharmaceutical diagnostic agents used in PET for Alzheimer's disease include three that bind to beta amyloid: florbetapir (2012); flutemetamol (2013); and florbetaben (2014); and one that binds to tau protein, flortaucipir (2020). Because many insurance companies in the United States do not cover this test, its use in clinical practice is largely limited to clinical trials as of 2018. Assessment of intellectual functioning, including memory testing, can further characterise the disease state. Medical organizations have created diagnostic criteria to ease and standardise the diagnostic process for practising physicians. Definitive diagnosis can only be confirmed when brain material is available, usually post-mortem, and can be examined histologically for senile plaques and neurofibrillary tangles.
== Signs and symptoms == Sydenham's chorea is characterized by the abrupt onset (sometimes within a few hours) of neurological symptoms, classically chorea, which are non-rhythmic, writhing or explosive involuntary movements. Usually all four limbs are affected, but there are cases reported where just one side of the body is affected (hemichorea). Typical chorea includes repeated wrist hyperextension, grimacing, and lip pouting. The fingers can move as if playing the piano. There may be tongue fasciculations ("bag of worms") and motor impersistence, for example, the "milkmaid sign" (grip strength fluctuates, as if hand milking a cow), or inability to sustain tongue protrusion (called jack-in-the-box tongue or serpentine tongue, as the tongue slides in and out of the mouth), or eye closure. There is usually a loss of fine motor control, which is particularly obvious in handwriting if the child is of school age. Speech is often affected (dysarthria), as is walking; legs will suddenly give way or flick out to one side, giving an irregular gait and the appearance of skipping or dancing. Underlying the abnormal movements is often low tone (hypotonia) which may not become obvious until treatment is started to suppress the chorea. The severity of the condition can vary from just some instability on walking and difficulty with handwriting, to the extreme of being wholly unable to walk, talk, or eat (chorea paralytica). Movements cease during sleep.
== Association football scandals == 1915 British football match-fixing scandal 1964 British football match-fixing scandal Bundesliga scandal (1965) 1971 Bundesliga scandal 1980 Italian football scandal – a match fixing scandal in Italian football involving several major teams. 1986 Totonero 1988 Mexico national football team scandal 1989 Maracanazo of the Chilean team 1993 French football bribery scandal – a match fixing scandal involving a 1992–93 French Division 1 match between Olympique de Marseille and Valenciennes, in which Valenciennes players were bribed by Olympique de Marseille president Bernard Tapie, through Marseille midfielder Jean-Jacques Eydelie. It is believed that Eydelie offered three Valenciennes players (Jorge Burruchaga, Christophe Robert and Jacques Glassman) ₣250,000 to "take the foot off of the gas" in a May 20 match between the sides, so that the team would be fresh to play in the Champions League final soon after. Marseille were subsequently stripped off the 1992–93 French Division 1 title, relegated to Division 2 and handed bans from all 1993 UEFA competitions. The French Football Federation also suspended Eydelie, Robert and Burruchaga, whilst Tapie was replaced as club president by Bernard Moreau. Tapie received a prison sentence of over two years, of which he served six months and received a ₣20,000 fine, whilst Eydelie, Robert, Burruchaga and Marseille general manager Jean-Pierre Bernès were all given prison sentences and fined. Eydelie's prison sentence was a suspended sentence.
Sources: en.wikipedia.org
Cuprates have a structure close to that of a two-dimensional material. Their superconducting properties are determined by electrons moving within weakly coupled copper-oxide (CuO2) layers. Neighbouring layers contain ions such as lanthanum, barium, strontium, or other atoms that act to stabilize the structures and dope electrons or holes onto the copper-oxide layers. The undoped "parent" or "mother" compounds are Mott insulators with long-range antiferromagnetic order at sufficiently low temperatures. Single band models are generally considered to be enough to describe the electronic properties. The cuprate superconductors adopt a perovskite structure. The copper-oxide planes are checkerboard lattices with squares of O2− ions with a Cu2+ ion at the centre of each square. The unit cell is rotated by 45° from these squares. Chemical formulae of superconducting materials contain fractional numbers to describe the doping required for superconductivity. Several families of cuprate superconductors have been identified. They can be categorized by their elements and the number of adjacent copper-oxide layers in each superconducting block. For example, YBCO and BSCCO can be referred to as Y123 and Bi2201/Bi2212/Bi2223 depending on the number of layers in each superconducting block (n). The superconducting transition temperature peaks at an optimal doping value (p=0.16) and an optimal number of layers in each block, typically three. Possible mechanisms for cuprate superconductivity remain the subject of considerable debate and research.
Atherosclerosis Hyperglycemia from consumption of excess sugars (includes juices, sauces, alcohol) & processed Carbohydrates. Neoplasm Overeating Inactivity & lack of muscle strength. See Physical inactivity and Physical activity. Pancreatic cancer Trans fats
Tight scaly skin (Ichthyosis) Absence of ABCA12 gene (Ichthyosis) Swollen or puffy gums (Periodontitis/Gingivitis) Purulent drainage from lips (Improper Wound healing) Wide mouth which causes difficulty feeding and suckling Difficulty in feeding causes lack of adequate nutrition, dehydration and even death Skin that is more prone to infection Hindered pulmonary ventilation Hindered pulmonary ventilation
Supra, lock and key management systems Sicli, a supplier of fire extinguishers and hose reels in France and Switzerland Sensitech, a cold chain solutions provider based in the U.S. Taylor, a manufacturer of commercial foodservice equipment to service frozen desserts, beverages and grilled items UTEC, manufactures microprocessor-based controls for the HVAC and refrigeration industries
The 52nd G7 Summit was an annual summit of the G7 held from 15 to 17 June 2026 in Évian-les-Bains, Haute-Savoie, France. Évian-les-Bains previously hosted the 29th G8 summit in 2003. The 2026 summit therefore makes Évian the first French town to host a G7 or G8 leaders' summit twice. At the summit, leaders issued joint statements on Ukraine, the Middle East, critical minerals and global economic imbalances, among other issues.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.